Patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment plus placebo

patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral 420mg/day in 3 divided doses

COVID-19

Viral Pneumonia Human Coronavirus

Silymarin Oral at a dose of 420 mg/day in 3 divided doses.

Silymarin

Placebo

Cairo University

Silymarin in COVID-19 Pneumonia

Trial of Silymarin in Adults With COVID-19 Pneumonia

Defined as the time from randomization to an improvement of two points (from the status of randomization) on seven category ordinal scale or live discharge from the hospital, whichever comes first.

Clinical status as assessed with the seven-category ordinal scale on days 7 and 14

number of days patient remained with positive RT-PCR SARS-CoV-2 swab

Any adverse events whether related to medication or not

Khaled Mohammed Korany Salem

Assistant Lecturer

Group 1 (Control): Includes 25 patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + placebo Group 2 (Intervention): Includes 25 patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral at a dose of 420 mg/day in 3 divided doses.

lamyropsis cynaroides/nekroza

Silymarin in COVID-19 Pneumonia

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo